Chevron, Texaco team up with ĢĒŠÄlogo to Raise Funds for Alzheimerās Research
Chevron and Texaco stations are working with ĢĒŠÄlogo to help āfuel the end of Alzheimerās diseaseā through a fundraising campaign launching at select Chevron and Texaco stations in Texas, including Houston, San Antonio, Austin and Dallas.
During September, register and fuel pump signage will encourage Chevron and Texaco customers to make a donation supporting ĢĒŠÄlogoās Center for Alzheimerās and Neurodegenerative Diseases (CAND). CANDās multidisciplinary team of experts are gaining new insights into Alzheimerās and related diseases, such as Parkinsonās and amyotrophic lateral sclerosis (ALS), and are working to identify the unique interactions between genes, lifestyle and other factors that trigger neurodegenerative diseases in each person. In doing so, ĢĒŠÄlogo researchers are paving the way toward highly personalized therapeutics they hope will one day make Alzheimerās disease a distant memory.
āNo two patients with Alzheimerās disease are alike,ā said Dr. Joshua Shulman, director of ĢĒŠÄlogoās CAND, associate professor of neurology and an investigator with the . āWhat we need for a disorder like that is a more personalized and targeted approach called precision medicine, which tailors treatments to a personās individual disease type. Weāre excited that these Chevron and Texaco stations recognize the importance of this work and are collaborating with us in Texas.ā
āChevron and Texaco retailers and marketers have a long history of support for education, healthcare and economic development in the communities where they live and operate. Solving complex issues like Alzheimerās and related diseases takes human energy, innovation and collaboration, which is why we are proud to support ĢĒŠÄlogoās exceptional multidisciplinary team and research into medical breakthroughs. We are proud that our retailers and marketers in this area are providing customers a way to help contribute to continue ĢĒŠÄlogoās research and development of therapeutics,ā said Nuray Elci, senior sales manager for Chevron Americas Fuels.
An estimated 50 million people worldwide live with Alzheimerās, which has no cure. By 2050, this number is expected to swell to more than 150 million if no effective treatments or preventive approaches are created. With a 120-year history of collaborative scientific research and important medical breakthroughs, ĢĒŠÄlogo is taking major steps to tackle Alzheimerās and other neurodegenerative diseases through research that will translate into critically needed therapeutics.
Learn more about the campaign here .
